CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia
Article first published online: 20 JUN 2003
Copyright © 2003 Wiley-Liss, Inc.
American Journal of Hematology
Volume 73, Issue 3, pages 149–153, July 2003
How to Cite
Lee, J.-J., Cho, D., Chung, I.-J., Cho, S.-H., Park, K.-S., Park, M.-R., Ryang, D.-W. and Kim, H.-J. (2003), CD34 expression is associated with poor clinical outcome in patients with acute promyelocytic leukemia. Am. J. Hematol., 73: 149–153. doi: 10.1002/ajh.10337
- Issue published online: 20 JUN 2003
- Article first published online: 20 JUN 2003
- Manuscript Accepted: 15 MAR 2003
- Manuscript Received: 12 SEP 2002
- Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea. Grant Number: 01-PJ10-PG6-01GN16-0005
This study investigated the clinical characteristics and prognostic relevance of CD34 expression in 47 patients with acute promyelocytic leukemia (APL), showing t(15;17) or PML/RARα. Ten (21.3%) of the APL patients were CD34+. CD34 expression was associated with hypogranular morphology (P = 0.002) and hyperleukocytosis (P = 0.015). However, there were no statistically significant differences in age, sex, hemoglobin level, platelet count, or percentage of blasts between the CD34+ and CD34− APL groups. Multiplex RT-PCR analysis showed that the L-form (BCR1) and S-form (BCR3) were correlated with CD34− APL and CD34+ APL, respectively. Despite the lack of a difference in the complete remission rate, overall survival (OS) and disease-free survival (DFS) were significantly lower in the CD34+ group than in the CD34− group (P = 0.012 and P = 0.0051, respectively). By multivariate analysis, the CD34+ group showed a significant independent variable in DFS compared with the CD34− group, but this was not demonstrated for OS. In conclusion, CD34 expression in APL is a unique clinical feature associated with leukocytosis and atypical morphology with hypogranular pattern and is associated with a poor clinical outcome. Am. J. Hematol. 73:149–153, 2003. © 2003 Wiley-Liss, Inc.